They Called It Impossible for 40 Years — Here's Why I'm Both Thrilled and Furious
Daraxonrasib, the world's first broad-spectrum oral RAS(ON) inhibitor targeting the previously "undruggable" KRAS oncogene, was unveiled at ASCO 2026 as a transformative advance in metastatic pancreatic cancer treatment, drawing a standing ovation after the Phase 3 RASolute 302 trial demonstrated a near-doubling of median overall survival. Across 501 previously treated patients, the trial reported median overall survival of 13.2 months on daraxonrasib versus 6.7 months on chemotherapy — a hazard ratio of 0.40 (p<0.0001), representing a 60% reduction in death risk, with one-year survival rising from 18.7% to 53.3%, marking the first time any second-line agent had pushed median survival past one year in this indication. Unlike sotorasib, which targets only the KRAS G12C variant accounting for just 1–2% of pancreatic cancers, daraxonrasib simultaneously suppresses G12D (40%), G12V (29%), and G12R (15%) — the three mutations responsible for the overwhelming majority of KRAS-driven pancreatic cancer — establishing the proof of concept for broad-spectrum RAS inhibition as a viable therapeutic strategy. This clinical triumph, however, coexists with a structural contradiction: the projected monthly price of $30,547–$37,318 renders the drug effectively inaccessible to 85–90% of the 510,922 annual global pancreatic cancer patients, and the 31-year gap between KRAS discovery in 1982 and the NCI RAS Initiative's launch in 2013 exposes a long history of underfunding — $8,945 in NCI per-death research spending for pancreatic cancer versus $69,800 for breast cancer — that deserves as much attention as the breakthrough itself. Treatment effects vary significantly by individual, and as daraxonrasib is currently available only through expanded access prior to formal FDA approval, all treatment decisions must be made in consultation with a qualified oncologist.